The following is a summary of “Dysbetalipoproteinemia Is Associated With Increased Risk of Coronary and Peripheral Vascular Disease,” published in the January 2023 issue of Endocrinology & Metabolism by Paquette, et al.

Dysbetalipoproteinemia (DBL) is a condition in which residual lipoproteins build up in the plasma due to genetic apolipoprotein E malfunction and the coexistence of additional metabolic variables. Retrospective investigations have shown that these patients had a higher chance of developing a peripheral vascular disease (PVD) and coronary disease. For a study, researchers sought to assess the prevalence of atherosclerotic cardiovascular disease (ASCVD) and PVD in a cohort of DBL patients compared to normolipidemic controls. The incidence of familial hypercholesterolemia (FH) and DBL patients’ rates of ASCVD and PVD were compared as a secondary goal.

The study comprised 1,481 normolipidemic controls, 725 patients with FH, and 221 patients with DBL. Medical records were examined to gather the data.

Comparing patients with DBL to normolipidemic controls revealed an overall higher risk of PVD (hazard ratio [HR] 13.58, 95% CI 4.76-38.75) and ASCVD (HR 3.55, 95% CI 2.17-5.83) (P< .0001). In addition, patients with DBL had a higher incidence of PVD (HR 3.89, 95% CI 1.20-12.55, P =.02) when compared to those with FH.

They showed that the risks of ASCVD and PVD in DBL were >3-fold and >13-fold higher, respectively, than in normolipidemic controls. In addition, DBL had a roughly ∼4-fold higher risk of PVD than FH. To prevent the onset of ASCVD, adequate DBL screening was essential for enhancing therapeutic care for these patients.